ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
ADMA Biologics reported strong Q1 2025 financial results with total revenue of $114.8 million, up 40% year-over-year. The company achieved GAAP Net Income of $26.9 million (51% YoY increase) and Adjusted EBITDA of $47.9 million (81% YoY increase). ADMA received FDA approval for its yield enhancement process, expected to increase production output by 20% from the same plasma volume.
The company increased its guidance for FY 2025 and 2026, projecting total revenues of $500+ million and $625+ million respectively. ADMA authorized a $500 million share repurchase program, representing 8% of current market capitalization. The company's debt reorganization reduced cost of debt capital by 1.1%. ADMA now expects to achieve $1.1 billion in annual revenues before 2030, with anticipated margin expansion.
ADMA Biologics ha riportato solidi risultati finanziari del primo trimestre 2025 con un fatturato totale di 114,8 milioni di dollari, in crescita del 40% rispetto all'anno precedente. L'azienda ha registrato un utile netto GAAP di 26,9 milioni di dollari (aumento del 51% su base annua) e un EBITDA rettificato di 47,9 milioni di dollari (incremento dell'81% su base annua). ADMA ha ottenuto l'approvazione della FDA per il suo processo di miglioramento della resa, che dovrebbe aumentare la produzione del 20% dallo stesso volume di plasma.
L'azienda ha rivisto al rialzo le previsioni per il 2025 e il 2026, stimando ricavi totali rispettivamente superiori a 500 milioni e 625 milioni di dollari. ADMA ha autorizzato un programma di riacquisto azionario da 500 milioni di dollari, pari all'8% della capitalizzazione di mercato attuale. La riorganizzazione del debito ha ridotto il costo del capitale di debito dell'1,1%. ADMA ora prevede di raggiungere 1,1 miliardi di dollari di ricavi annuali entro il 2030, con un'espansione prevista dei margini.
ADMA Biologics reportó sólidos resultados financieros del primer trimestre de 2025 con ingresos totales de 114,8 millones de dólares, un aumento del 40% interanual. La compañía alcanzó un Ingreso Neto GAAP de 26,9 millones de dólares (incremento del 51% interanual) y un EBITDA Ajustado de 47,9 millones de dólares (aumento del 81% interanual). ADMA recibió la aprobación de la FDA para su proceso de mejora del rendimiento, que se espera aumente la producción en un 20% a partir del mismo volumen de plasma.
La empresa elevó sus previsiones para los años fiscales 2025 y 2026, proyectando ingresos totales de más de 500 millones y 625 millones de dólares respectivamente. ADMA autorizó un programa de recompra de acciones por 500 millones de dólares, que representa el 8% de la capitalización de mercado actual. La reorganización de la deuda redujo el costo del capital de deuda en un 1,1%. ADMA ahora espera alcanzar 1.100 millones de dólares en ingresos anuales antes de 2030, con una expansión anticipada de márgenes.
ADMA Biologics는 2025년 1분기 재무 실적에서 총 매출 1억 1,480만 달러를 기록하며 전년 대비 40% 증가한 강력한 성과를 보고했습니다. 회사는 GAAP 순이익 2,690만 달러(전년 대비 51% 증가)와 조정 EBITDA 4,790만 달러(전년 대비 81% 증가)를 달성했습니다. ADMA는 FDA로부터 수율 향상 프로세스 승인을 받아 동일한 혈장량에서 생산량을 20% 증가시킬 것으로 기대됩니다.
회사는 2025년과 2026년 회계연도 가이던스를 상향 조정하여 각각 5억 달러 이상 및 6억 2,500만 달러 이상의 총 매출을 예상하고 있습니다. ADMA는 현재 시가총액의 8%에 해당하는 5억 달러 규모의 자사주 매입 프로그램을 승인했습니다. 부채 재조정으로 부채 자본 비용이 1.1% 감소했습니다. ADMA는 2030년 이전에 연간 매출 11억 달러 달성을 기대하며, 마진 확대도 예상하고 있습니다.
ADMA Biologics a annoncé de solides résultats financiers pour le premier trimestre 2025 avec un chiffre d'affaires total de 114,8 millions de dollars, en hausse de 40 % par rapport à l'année précédente. La société a réalisé un résultat net GAAP de 26,9 millions de dollars (augmentation de 51 % en glissement annuel) et un EBITDA ajusté de 47,9 millions de dollars (augmentation de 81 % en glissement annuel). ADMA a obtenu l'approbation de la FDA pour son procédé d'amélioration du rendement, qui devrait augmenter la production de 20 % avec le même volume de plasma.
L'entreprise a relevé ses prévisions pour les exercices 2025 et 2026, prévoyant des revenus totaux de plus de 500 millions et 625 millions de dollars respectivement. ADMA a autorisé un programme de rachat d'actions de 500 millions de dollars, représentant 8 % de la capitalisation boursière actuelle. La réorganisation de la dette a réduit le coût du capital d'emprunt de 1,1 %. ADMA prévoit désormais d'atteindre 1,1 milliard de dollars de revenus annuels avant 2030, avec une expansion prévue des marges.
ADMA Biologics meldete starke Finanzergebnisse für das erste Quartal 2025 mit einem Gesamtumsatz von 114,8 Millionen US-Dollar, was einem Anstieg von 40 % im Jahresvergleich entspricht. Das Unternehmen erzielte einen GAAP-Nettogewinn von 26,9 Millionen US-Dollar (51 % Steigerung im Jahresvergleich) und ein bereinigtes EBITDA von 47,9 Millionen US-Dollar (81 % Steigerung im Jahresvergleich). ADMA erhielt die FDA-Zulassung für seinen Ertragssteigerungsprozess, der voraussichtlich die Produktionsleistung um 20 % bei gleichem Plasmavolumen erhöht.
Das Unternehmen hat seine Prognosen für das Geschäftsjahr 2025 und 2026 angehoben und erwartet einen Gesamtumsatz von über 500 Millionen bzw. 625 Millionen US-Dollar. ADMA genehmigte ein Aktienrückkaufprogramm in Höhe von 500 Millionen US-Dollar, was 8 % der aktuellen Marktkapitalisierung entspricht. Die Umschuldung reduzierte die Kapitalkosten um 1,1 %. ADMA rechnet nun damit, vor 2030 eine jährliche Umsatzhöhe von 1,1 Milliarden US-Dollar zu erreichen, mit erwarteter Margenausweitung.
- FDA approval of yield enhancement process to increase production output by 20%
- Q1 2025 revenue grew 40% YoY to $114.8M with 53.2% gross margin
- Adjusted EBITDA increased 81% YoY to $47.9M
- Authorization of $500M share repurchase program
- Debt reorganization reduced cost of debt capital by 1.1%
- Strong balance sheet with $171M in cash and receivables
- Increased FY 2025/2026 revenue guidance to $500M/$625M+
- One-time voluntary product withdrawals affected Q1 2025 revenues
Insights
ADMA reports exceptional Q1 with 40% revenue growth, FDA approval boosting production capacity, increased guidance, and $500M buyback, signaling accelerating performance.
ADMA Biologics has delivered exceptional Q1 2025 financial results, with revenue reaching
The gross margin expansion to
The FDA approval of ADMA's yield enhancement production process represents a significant competitive advantage. As the first U.S. producer of plasma-derived products to receive such approval, ADMA can now increase its finished immunoglobulin output by
ADMA's increased financial guidance reflects management's growing confidence, with FY 2025 and 2026 revenue now expected to exceed
From a capital allocation perspective, the announcement of a
ADMA's U.S.-based manufacturing footprint provides insulation from international supply chain disruptions affecting multinational competitors, while the robust intellectual property protection for ASCENIV through at least 2035 provides an unusually long runway for branded growth compared to traditional pharmaceutical products.
1Q 2025 Total Revenue of
1Q 2025 GAAP Net Income of
1Q 2025 Adjusted EBITDA(2) of
1Q 2025 Adjusted Net Income(3) of
1Q 2025 Total Cash and Receivables Grew to Approximately
FDA Approved Yield Enhancement Process Anticipated to Provide
FY 2025 and 2026 Total Revenue Guidance Increased to More than
FY 2025 Adjusted Net Income Guidance Reiterated to be
FY 2025 and 2026 Adjusted EBITDA Guidance Increased to More Than
Authorization of
Debt Reorganization Reduces ADMA’s Cost of Debt Capital by
Total Annual Revenues Expected to be Realized Prior to 2030 Now Increased to
RAMSEY, N.J. and BOCA RATON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its first quarter 2025 financial results and provided a business update.
"The start to 2025 has been a transformational period for ADMA, with the recent U.S. Food and Drug Administration (FDA) approval of our yield enhancement production process, which we believe paves the way for meaningful forward looking revenue growth and margin expansion, ultimately creating durable stockholder value. ADMA delivered outstanding financial and operational results in the first quarter of 2025, with total reported revenues and Adjusted EBITDA growing by
Mr. Grossman continued, "We believe our U.S.-based manufacturing footprint and fully controlled, end-to-end supply chain provide substantial insulation from geopolitical and global trade challenges potentially impacting multi-national pharma competitors. With long-term, high-titer plasma supply agreements in place and record internal plasma collections, we believe the Company is well-positioned to scale efficiently and deliver on the upwardly revised near- and long-term financial guidance. ADMA’s strong balance sheet, including approximately
"We anticipate meaningful forward-looking financial uplift from our recently approved yield enhancement production process, which is expected to increase finished IG output by
Financial Guidance:
Potential benefits and accretion from the FDA approval of ADMA’s yield enhancement production process remain excluded from the upwardly revised 2025 guidance ranges and are conservatively contemplated in the increased 2026 guidance ranges.
- FY 2025 and 2026 total revenue increased to more than
$500 million and$625 million or more, respectively - FY 2025 Adjusted Net Income reaffirmed to be
$175 million or more and FY 2026 Adjusted Net Income is now increased to$245 million or more - FY 2025 and 2026 Adjusted EBITDA increased to more than
$235 million and$340 million or more, respectively - Pre-2030 total annual revenue guidance increased to
$1.1 billion or more, with anticipated outsized earnings growth from current margin levels
Recent 1Q 2025 Business Updates & Objectives:
- Insulated business model. ADMA is a U.S.-based company with all manufacturing operations, end-market sales, and customer engagements conducted exclusively within the United States. The tariffs that have been implemented on foreign goods, services and manufacturing are not anticipated to have an impact on ADMA and its supply chain or production operations. We believe our strategic infrastructure not only ensures enhanced supply chain robustness, resilience and regulatory compliance but also aligns with increasing federal and private sector preferences for U.S.-made products and services. By maintaining complete operational control within the U.S., we believe ADMA is uniquely well-positioned to capitalize on national economic incentives and deliver reliable, secure, and high-quality offerings to its domestic customer base.
- FDA approval of innovative yield enhancement production process. The recent regulatory approval represents a pivotal milestone for ADMA, unlocking meaningful acceleration in our forecasted revenue and earnings trajectory beginning in late 2025 and accelerating further into 2026 and beyond. As the first U.S. producer of plasma-derived products to achieve regulatory approval for its innovative yield enhancement production process, ADMA continues to demonstrate its leadership in modernizing and innovating plasma fractionation through agile, forward-thinking scientific development and execution.
- Robust ASCENIV demand. Across all forward-looking demand metrics, ASCENIV continues to trend to record highs through 1Q 2025 and subsequent periods; as a result, the Company expects ASCENIV’s total revenue share to expand throughout 2025 and beyond. As ASCENIV’s benefit in real-world patient outcomes continues and long-term high-titer plasma supply contracts ramp up, ADMA anticipates accelerating ASCENIV’s new patient starts and deepening penetration in existing institutions, which would significantly expand its peak revenue potential beyond current levels.
- Debt reorganization further reduces ADMA’s cost of debt capital. ADMA has reorganized its outstanding debt, by paying down all but
$2.5 million of its term loan with Ares Capital with available proceeds from its revolving credit facility. The reorganization provides for a1.1% nominal reduction of ADMA’s cost of debt. Additionally, as forecasted cash continues to grow, ADMA remains committed to optimizing its capital structure and continuing to organically pay down its total debt.
- Strengthened balance sheet and optimizing cost of capital. ADMA ended the first quarter with
$171 million in total cash and receivables. The Company anticipates further balance sheet improvements in 2025, driven by projected Adjusted EBITDA growth, sustained cash generation, and continued optimization of its capital structure. - Authorization of
$500 million share repurchase program. In keeping with ADMA’s alignment with stockholders and unwavering commitment to generating sustained stockholder value, the Company has recently authorized a common stock repurchase program of up to$500 million , representing approximately8% of ADMA’s current market capitalization. The Company will be opportunistic in deploying these repurchases, which we believe will be enabled by a strong balance sheet position and forecasted earnings and cash generation. - Leveraging robust IP estate and innovative R&D engine. ADMA anticipates generating initial, proof of concept animal data before year-end 2025 for its lead R&D pipeline program, SG-001, a hyperimmune globulin targeting S. pneumonia. If approved, SG-001 represents potential upside to the current financial guidance, and ADMA believes the product has the potential to generate
$300 -500 million or more in high margin annual revenue, with IP protection through at least 2037. - Unique asset durability and terminal value. ASCENIV’s robust intellectual property estate, covering proprietary plasma screening assays, unique plasma pooling, and methods of IG use, secures brand protection through at least 2035, with potential IP extensions beyond 2035. The Company is confident that regulatory barriers and proprietary know-how further safeguard ASCENIV’s branded growth, potentially well beyond 2035. This comprehensive IP portfolio, encompassing IG treatment for all viral-induced respiratory infections, supports ADMA’s expectation that ASCENIV is well-positioned to deliver long-term branded growth. We believe ASCENIV may generate one of the most durable earnings streams in the sector.
First Quarter 2025 Financial Results:
Total reported revenue was
Gross profit was
GAAP Net Income was
Adjusted Net Income was
Adjusted EBITDA was
Conference Call Information:
To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available, located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
Use of Non-GAAP Financial Measures
This press release includes certain non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The Company believes Adjusted Total Revenue, Adjusted EBITDA and Adjusted Net Income are useful to investors in evaluating the Company’s financial performance. The Company uses Adjusted Total Revenue, Adjusted EBITDA and Adjusted Net Income as key performance measures because we believe that they facilitate operating performance comparisons from period to period that exclude potential differences driven by the impact of variations of non-cash items such as depreciation and amortization, as well as, in the case of Adjusted Total Revenue, certain non-recurring items, in the case of Adjusted EBITDA, stock-based compensation or certain non-recurring items, and in the case of Adjusted Net Income, certain non-recurring items. The Company believes that investors should have access to the same set of tools used by our management and board of directors to assess our operating performance. Adjusted Total Revenue, Adjusted EBITDA and Adjusted Net Income should not be considered as measures of financial performance under GAAP, and the items excluded from Adjusted Total Revenue, Adjusted EBITDA and Adjusted Net Income are significant components in understanding and assessing the Company’s financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income/loss, cash flows from operations, or any other performance measures derived in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. Please refer to the tables below for the reconciliation of GAAP measures to these non-GAAP measures for applicable periods.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “confident,” “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “position us,” “should,” “could,” “would,” “may,” “potential,” “opportunity” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the Company’s financial performance; total revenue, GAAP Net Income, Adjusted Net Revenue, Adjusted EBITDA, Adjusted Net Income and margins guidance in future periods and related timing in connection therewith; revenue growth, margin expansion and production output capacity as a result of FDA approval of the yield enhancement process, and timing related thereto, as well as commercial and R&D program benefits as a result of such approval; the Company’s insulation from broader equity and credit market volatility; the expected benefits of our newly approved stock repurchase program; the impact of tariffs on the Company’s supply chain or production operations, and the benefits of being U.S. based; ASCENIV’s total revenue share and growth; ADMA’s senior credit facility and plans to further pay down its outstanding debt; our balance sheet; the benefits of our long-term, high-titer plasma supply agreements and impact on ASCENIV growth and financial performance; ability to deliver stockholder value; statements regarding SG-001 and revenue potential; and ASCENIV’s intellectual property estate. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
(1) Adjusted Total Revenue is a non-GAAP financial measure. For a reconciliation of Adjusted Revenue to the most comparable GAAP measure, see the reconciliation included in the financial tables.
(2) Adjusted EBITDA is a non-GAAP financial measure. For a reconciliation of Adjusted EBITDA to the most comparable GAAP measure, see the reconciliation included in the financial tables.
(3) Adjusted Net Income is a non-GAAP financial measure. For a reconciliation of Adjusted Net Income to the most comparable GAAP measure, see the reconciliation included in the financial tables. All non-GAAP adjustments are presented pre-tax.
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
| ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS | |||||||
| March 31, | December 31, | ||||||
| 2025 | 2024 | ||||||
| (Unaudited) | |||||||
| ASSETS | (In thousands, except share data) | ||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 71,625 | $ | 103,147 | |||
| Accounts receivable, net | 99,412 | 49,999 | |||||
| Inventories | 172,188 | 170,235 | |||||
| Prepaid expenses and other current assets | 8,589 | 8,029 | |||||
| Total current assets | 351,814 | 331,410 | |||||
| Property and equipment, net | 57,710 | 54,707 | |||||
| Intangible assets, net | 452 | 460 | |||||
| Goodwill | 3,530 | 3,530 | |||||
| Deferred tax assets, net | 80,855 | 84,280 | |||||
| Right-to-use assets | 8,020 | 8,634 | |||||
| Deposits and other assets | 8,188 | 5,657 | |||||
| TOTAL ASSETS | $ | 510,569 | $ | 488,678 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 20,607 | $ | 20,219 | |||
| Accrued expenses and other current liabilities | 31,560 | 33,962 | |||||
| Current portion of deferred revenue | 143 | 143 | |||||
| Current portion of lease obligations | 1,188 | 1,218 | |||||
| Total current liabilities | 53,498 | 55,542 | |||||
| Senior notes payable, net of discount | 72,527 | 72,337 | |||||
| Deferred revenue, net of current portion | 1,512 | 1,547 | |||||
| End of term fee | 1,313 | 1,313 | |||||
| Lease obligations, net of current portion | 8,298 | 8,561 | |||||
| Other non-current liabilities | 2 | 360 | |||||
| TOTAL LIABILITIES | 137,150 | 139,660 | |||||
| COMMITMENTS AND CONTINGENCIES | |||||||
| STOCKHOLDERS' EQUITY | |||||||
| Preferred Stock, | |||||||
| no shares issued and outstanding | - | - | |||||
| Common Stock - voting, | |||||||
| 238,532,252 and 236,620,545 shares issued and outstanding at March 31, 2025 and December 31, 2024 | 24 | 24 | |||||
| Additional paid-in capital | 655,074 | 657,577 | |||||
| Accumulated deficit | (281,679 | ) | (308,583 | ) | |||
| TOTAL STOCKHOLDERS' EQUITY | 373,419 | 349,018 | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 510,569 | $ | 488,678 | |||
| ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
| Three Months ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| (Unaudited, in thousands, except share and per share data) | ||||||||
| REVENUES | $ | 114,802 | $ | 81,875 | ||||
| Cost of product revenue | 53,705 | 42,767 | ||||||
| Gross profit | 61,097 | 39,108 | ||||||
| OPERATING EXPENSES: | ||||||||
| Research and development | 826 | 450 | ||||||
| Plasma center operating expenses | 1,286 | 1,005 | ||||||
| Amortization of intangible assets | 25 | 193 | ||||||
| Selling, general and administrative | 24,079 | 15,639 | ||||||
| Total operating expenses | 26,216 | 17,287 | ||||||
| INCOME FROM OPERATIONS | 34,881 | 21,821 | ||||||
| OTHER INCOME (EXPENSE): | ||||||||
| Interest income | 608 | 384 | ||||||
| Interest expense | (1,975 | ) | (3,769 | ) | ||||
| Other expense | (64 | ) | (35 | ) | ||||
| Other expense, net | (1,431 | ) | (3,420 | ) | ||||
| INCOME BEFORE INCOME TAXES | 33,450 | 18,401 | ||||||
| Provision for income taxes | 6,546 | 595 | ||||||
| NET INCOME | $ | 26,904 | $ | 17,806 | ||||
| BASIC EARNINGS PER COMMON SHARE | $ | 0.11 | $ | 0.08 | ||||
| DILUTED EARNINGS PER COMMON SHARE | $ | 0.11 | $ | 0.08 | ||||
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING: | ||||||||
| Basic | 237,775,476 | 228,874,847 | ||||||
| Diluted | 244,676,350 | 236,414,374 | ||||||
| NON-GAAP RECONCILIATION RECONCILIATION OF GAAP TOTAL REVENUE TO ADJUSTED TOTAL REVENUE (1) | ||||||||
| Three months ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| (In thousands) | ||||||||
| Revenues | $ | 114,802 | $ | 81,875 | ||||
| Customer credits related to the Voluntary Withdrawal | 3,837 | - | ||||||
| Adjusted Revenues | $ | 118,639 | $ | 81,875 | ||||
| NON-GAAP RECONCILIATION RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA (2) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| (In thousands) | ||||||||
| Net income | $ | 26,904 | $ | 17,806 | ||||
| Depreciation | 1,944 | 1,921 | ||||||
| Amortization | 25 | 193 | ||||||
| Income taxes | 6,546 | 595 | ||||||
| Interest expense | 1,975 | 3,769 | ||||||
| EBITDA | 37,393 | 24,284 | ||||||
| Stock-based compensation | 4,624 | 2,141 | ||||||
| Customer credits related to the Voluntary Withdrawal | 3,837 | - | ||||||
| Yield Enhancement | 902 | - | ||||||
| Non-recurring professional fees (a) | 1,182 | - | ||||||
| Adjusted EBITDA | $ | 47,939 | $ | 26,425 | ||||
| (a) Non-recurring professional fees represent incremental costs associated with a vendor change that we do not expect to incur in future periods. | ||||||||
| NON-GAAP RECONCILIATION RECONCILIATION OF GAAP NET INCOME TO ADJUSTED NET INCOME (3) | ||||||||
| Three months ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| (In thousands) | ||||||||
| Net income | $ | 26,904 | $ | 17,806 | ||||
| Stock-based compensation modifications (pre-tax) | 474 | - | ||||||
| Customer credits related to the Voluntary Withdrawal (pre-tax) | 3,837 | - | ||||||
| Yield Enhancement (pre-tax) | 902 | - | ||||||
| Non-recurring professional fees (pre-tax) (a) | 1,182 | - | ||||||
| Adjusted net income (b) | $ | 33,299 | $ | 17,806 | ||||
| (a) Non-recurring professional fees represent incremental costs associated with a vendor change that we do not expect to incur in future periods. | ||||||||
| (b) Excludes estimated tax effect of the add-backs of | ||||||||
FAQ
What were ADMA Biologics' Q1 2025 financial results?
What is ADMA's new revenue guidance for 2025 and 2026?
How will ADMA's FDA-approved yield enhancement process impact production?
What is the size of ADMA's share repurchase program?
How much cash does ADMA Biologics have as of Q1 2025?
